The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Autologous Stem-Cell Transplantation As First-Line Therapy in Peripheral T-Cell Lymphomas: Results of a Prospective Multicenter Study
Abstract
Purpose: Peripheral T-cell lymphomas (PTCLs) are rare malignancies with poor outcome after conventional chemotherapy. The role of myeloablative therapy and autologous stem-cell transplantation (autoSCT) is still unclear. Therefore, we initiated the first prospective multicenter study on upfront autoSCT in PTCL and recently reported good feasibility and efficacy of this approach. Here, we present the final analysis of the study. Patients and Methods: The treatment regimen consisted of four to six cycles of cyclophosphamide, doxorubicin, vincristine, and prednisone followed by mobilizing therapy with either the dexamethasone, carmustine, melphalan, etoposide, and cytarabine protocol or the etoposide, methylprednisolone, cytarabine, and cisplatin protocol and stem-cell collection. Patients in complete remission (CR) or partial remission (PR) underwent myeloablative chemoradiotherapy (fractionated total-body irradiation and high-dose cyclophosphamide) and autoSCT. Results: From June 2000 to April 2006, 83 patients were enrolled onto the study. Main subgroups were PTCL not specified (n = 32) and angioimmunoblastic T-cell lymphoma (n = 27). Fifty-five (66%) of the 83 patients received transplantation. The main reason for not receiving autoSCT was progressive disease. In an intent-to-treat analysis, the overall response rate after myeloablative therapy was 66% (56% CR and 8% PR). With a median follow-up time of 33 months, 43 patients are alive; the estimated 3-year overall and disease-free survival rates for patients in CR (calculated from CR to the date of relapse) and 3-year progression-free survival rate were 48%, 53%, and 36%, respectively. Conclusion: The results of this prospective study suggest a substantial impact on outcome for upfront autoSCT in PTCL and should be further evaluated in randomized trials. Pretransplantation treatment needs to be improved to increase the transplantation rate.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas
Cheson, B. D., Horning, S. J., Coiffier, B., Shipp, M. A., Fisher, R. I., Connors, J. M., Lister, T. A., Vose, J., Grillo-López, A., Hagenbeek, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.4.1244 · Cited by 3,486
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
Rajkumar, S. V., Blood, E., Vesole, D., Fonseca, R., & Greipp, P. R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0221 · Cited by 865
Savage, K. J., Harris, N. L., Vose, J. M., Ullrich, F., Jaffe, E. S., Connors, J. M., Rimsza, L., Pileri, S. A., Chhanabhai, M., Gascoyne, R. D., et al. (2008) · Blood · doi:10.1182/blood-2008-01-134270 · Cited by 863
Gallamini, A. (2004) · Blood · doi:10.1182/blood-2003-09-3080 · Cited by 598
ALK+ lymphoma: clinico-pathological findings and outcome.
Falini, B., Pileri, S. A., Zinzani, P. L., Carbone, A., Zagonel, V., Wolf‐Peeters, C. D., Verhoef, G. E. G., Menestrina, F., Todeschini, G., Paulli, M., et al. (1999) · PubMed · doi:10.1182/blood.v93.8.2697 · Cited by 560
Gascoyne, R. D., Aoun, P., Wu, D., Chhanabhai, M., Skinnider, B. F., Greiner, T. C., Morris, S. W., Connors, J. M., Vose, J. M., Viswanatha, D. S., et al. (1999) · Blood · doi:10.1182/blood.v93.11.3913 · Cited by 524
Gisselbrecht, C., Gaulard, P., Lepage, É., Coiffier, B., Brière, J., Haïoun, C., Cazals-Hatem, D. L., Bosly, A., Xerri, L., Tilly, H., et al. (1998) · PubMed · doi:10.1182/blood.v92.1.76.413a19_76_82 · Cited by 437
Haioun, C., Lepage, E., Gisselbrecht, C., Salles, G., Coiffier, B., Brice, P., Bosly, A., Morel, P., Nouvel, C., Tilly, H., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.16.3025 · Cited by 421
Rüdiger, T., Weisenburger, D. D., Anderson, J. R., Armitage, J. O., Diebold, J., MacLennan, K. A., Nathwani, B. N., Ullrich, F., & Müller-Hermelink, H. K. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf033 · Cited by 419
Self-citationSavage, K. J., Chhanabhai, M., Gascoyne, R. D., & Connors, J. M. (2004) · Annals of Oncology · doi:10.1093/annonc/mdh392 · Cited by 363
Enblad, G., Hagberg, H., Erlanson, M., Lundin, J., MacDonald, A. P., Repp, R., Schetelig, J., Seipelt, G., & Österborg, A. (2004) · Blood · doi:10.1182/blood-2003-10-3389 · Cited by 327
Gallamini, A., Zaja, F., Patti, C., Billio, A., Specchia, M. R., Tucci, A., Levis, A., Manna, A., Secondo, V., Rigacci, L., et al. (2007) · Blood · doi:10.1182/blood-2007-02-074641 · Cited by 309
Coiffier, B., Brousse, N., Peuchmaur, M., Berger, F., Gisselbrecht, C., Bryon, P. A., & Diebold, J. (1990) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a057673 · Cited by 269
Liu, Y., Pop, R., Sadegh, C., Brugnara, C., Haase, V. H., & Socolovsky, M. (2006) · Blood · doi:10.1182/blood-2005-11-4458 · Cited by 216
Mercadal, S., Briones, J., Xicoy, B., Pedro, C., Escoda, L., Estany, C., Camós, M., Colomo, L., Espinosa, Í., Martínez, S., et al. (2008) · Annals of Oncology · doi:10.1093/annonc/mdn022 · Cited by 198
Ascani, S., Zinzani, P. L., Gherlinzoni, F., Sabattini, E., Briskomatis, A., Vivo, A. D., Piccioli, M., Orcioni, G. F., Pieri, F., Goldoni, A., et al. (1997) · Annals of Oncology · doi:10.1023/a:1008200307625 · Cited by 136
Kim, J. G., Sohn, S. K., Chae, Y. S., Cho, Y. Y., Yang, D., Lee, J., Kim, H., Shin, H. J., Chung, J. S., Cho, G.-J., et al. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0469-9 · Cited by 115
Clinical significance of immunophenotype in diffuse aggressive non-Hodgkin's lymphoma.
Armitage, J. O., Vose, J. M., Linder, J., Weisenburger, D. D., Harrington, D. S., Casey, J., Bierman, P. J., Sorensen, S., Hutchins, M., & Moravec, D. F. (1989) · Journal of Clinical Oncology · doi:10.1200/jco.1989.7.12.1783 · Cited by 96
Cited by
Horwitz, S., O'Connor, O. A., Pro, B., Illidge, T., Fanale, M., Advani, R., Bartlett, N. L., Christensen, J. H., Morschhauser, F., Domingo-Domenech, E., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32984-2 · Cited by 739
Self-citationUp-Front Autologous Stem-Cell Transplantation in Peripheral T-Cell Lymphoma: NLG-T-01
d'Amore, F., Relander, T., Lauritzsen, G. F., Jantunen, E., Hagberg, H., Anderson, H., Holte, H., Österborg, A., Merup, M., Brown, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.2719 · Cited by 594
Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., Witte, T. D., Dini, G., Einsele, H., Gaspar, H. B., Gratwohl, A., Passweg, J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.141 · Cited by 388
Self-citationFoss, F. M., Zinzani, P. L., Vose, J. M., Gascoyne, R. D., Rosen, S. T., & Tobinai, K. (2011) · Blood · doi:10.1182/blood-2010-05-231548 · Cited by 353
Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin
Horwitz, S. M., Advani, R. H., Bartlett, N. L., Jacobsen, E. D., Sharman, J. P., O’Connor, O. A., Siddiqi, T., Kennedy, D. A., & Oki, Y. (2014) · Blood · doi:10.1182/blood-2013-12-542142 · Cited by 352
Metadata
- Authors
- Reimer, P., Rüdiger, T., Geissinger, E., Weissinger, F., Nerl, C., Schmitz, N., Engert, A., Einsele, H., Müller-Hermelink, H. K., & Wilhelm, M.
- Venue
- Journal of Clinical Oncology
- Published
- 2009-01-01
- Volume
- 27
- Issue
- 1
- Pages
- 106-113
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2162389158
- Cited by
- 427
- References
- 19
- FWCI
- 12.85
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.